|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48 TWD | +1.05% |
|
+4.12% | -26.27% |
Tanvex BioPharma, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was TWD 61.41 million compared to TWD 22.4 million a year ago. Net loss was TWD 2,137.1 million compared to TWD 1,641.13 million a year ago.
Basic loss per share from continuing operations was TWD 16.58 compared to TWD 13.95 a year ago. Diluted loss per share from continuing operations was TWD 16.58 compared to TWD 13.95 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -26.27% | 241M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
TANVEX BIOPHARMA, INC. 
